PRO-VAC WORKSHOP ON ECONOMIC ANALYSIS TO SUPPORT DECISION-MAKING ON VACCINE INTRODUCTION

Immunization Unit, PAHO. Washington – 5-8 September 2006

References

Book 2 – Cost-Effectiveness Analysis

Influenza Vaccination

1. Meltzer, MI, Neuzil KM, Griffin MR, Fukuda K. An economic analysis of annual influenza vaccination of children. Vaccine 23 (2005) 1004–1014.
2. Tuner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Adams KR, Nicholson KG. The Cost Effectiveness of Influenza Vaccination of Healthy Adults 50-64 Years of Age. Vaccine. 2006; 24: 1035-1043.

Rotavirus Vaccination

3. Fisher T, Duc-Anh D, Antil L, Cat NL, Kilgore, P, Thiem V, Rheingans R, Tho L, Glass R, Bresee J. Health Care Cost of Diarrheal Disease and Estimates of the Cost-Effectiveness of Rotavirus Vaccination in Vietnam. Journal of Infectious Diseases. 2005; 192:1720-6.
4. Podewils L, Antil L, Hummelman E, Bresee J, Parashar U, Rheingans R. Projected Cost-Effectivess of Rotavirus Vaccination for Children in Asia. Journal of Infectious Diseases. 2005:192:S133-145.
5. Walker D, Rheingans R. Cost-Effectiveness of Rotavirus Vaccines. Expert Rev. Pharmacoeconomics Outcomes Research. Future Drugs Ltd. 2005; 5(5), 593-601.
6. WHO. Guidelines for estimating the economic burden of diarrhoeal disease with focus on assessing the costs of rotavirus diarrhea. WHO/IVB/05.10. 2005. WHO, Geneva.

Human Papillomavirus Vaccination

7. Goldie S. et al. Cost-effectiveness of Cervical-cancer Screening in Five Developing Countries. *NEJM,* 2005;353:2158-68
8. Goldie S, Kohli M, Grima D, Weinstein M, Wright T, Bosch F, Franco E. Projected Clinical Benefits and Cost Effectiveness of Human Papillomavirus 16/18 Vaccine. Journal of National Cancer Institute. April, 2004; 96:8. 604-15.
9. Sanders G, Taira A. Cost-Effectiveness of a Potential Vaccine for Human Papillomavirus. Emergency Infectious Diseases. 2003.

Vaccination Against Pneumococcal Diseases

10. Garcia, S et al. Pneumoccocal disease and vaccination in the Americas: and agenda for accelerated vaccine introduction. Pan American Jounral of Public Health; 2006; 19(5):340-348.

11. Lieu TA, Ray GT, Black SB et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000 Mar 15;283(11):1460-8.
12. Ray GT et al. Cost-effectiveness of pneumococcal conjugate vaccine – evidence from first 5 years of use in the United States incorporating herd effects. The pediatric Infectiuos Diseases Journal, 2006; 25(6):494-501.

Book 3 - Methods and Guidelines

13. Musgrove P and Fox-Rushby J. Cost-Effectiveness Analysis for Priority Setting. Disease Control Priorities in Developing Countries. 2nd Edition. New York: Oxford University Press.2006; 271-286.
14. Brenzel L, Wolfson L, Fox-Rushby J, Miller M, and Halsey N. Vaccine Preventable Diseases. Disease Control Priorities in Developing Countries. 2006. 2nd Edition. New York: Oxford University Press. 389-412.
15. Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life-years (DALY) in cost-effectiveness analysis.Health Policy and Planning; 16(3): 326-331.
16. Iglesias, CP; Drummonds, MF; Rovira, J; for the NEVALAT Group. Health-care decision making processes in Latin-America: Problems and prospects for the use of economic evaluation. International Journal of Technology Assessment in Health Care, 2005; 21(1): 1-14.
17. WHO. WHO guide to cost-effectiveness analysis. What is generalized cost-effectiveness analysis. Edited by Tan-Torres Edejer,T.; Baltussen,R.; Adam,T.; Hutubessy,R.; Acharya,A.; Evans,D.B.; Murray,C.J.L. 1st edition, 2003. WHO, Geneva.
18. WHO. WHO guide to cost-effectiveness analysis. Summary of recommendations. Edited by Tan-Torres Edejer,T.; Baltussen,R.; Adam,T.; Hutubessy,R.; Acharya,A.; Evans,D.B.; Murray,C.J.L. 1st edition, 2003. WHO, Geneva.
19. WHO. Guidelines for estimating costs of introducing new vaccines into the national immunization system. WHO/V&B/02.11, WHO, Geneva
20. PAHO. Guia operativa para introducción de nuevas vacunas. Versión preliminar, Septiembre, 2006. Adapted from: WHO, Vaccine introduction Guidelines. Adding a vaccine to a national immunization programme: decision and implementation. WHO/IVB/05.18. 2005. WHO, Geneva.
21. WHO. Immunization – An investment in life: Pan American Health Organization Revolving Fund.
22. WHO. Immunization – An investment in life: Pandemic influenza vaccines: development, supply and finance issues.
23. WHO. Immunization – An investment in life: Developing country vaccine manufacturers and sustainability of vaccine supply.

All references have been translated into spanish for Pro-Vac workshop with authorization from the authors and the publisher.